Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kyowa Kirin Sets Up New Firm for Nesp Authorized Biosimilar
Kyowa Hakko Kirin said on January 31 that it has established a new company, Kyowa Kirin Frontier, which will be working to obtain Japanese regulatory approval for an authorized biosimilar version of its core renal anemia treatment Nesp (darbepoetin alfa).…
To read the full story
Related Article
- Kyowa Kirin Says It’s Steadily Pursuing Nesp Authorized Biosimilar Program, but Silent on Details
August 1, 2018
- Japan Biosimilar Association Says “Authorized Biosimilars” Could Mar Industry Development
May 17, 2017
- New Firm for Nesp Biosimilar Will Broaden Options: Kyowa Kirin President
February 2, 2017
- Kyowa Kirin’s 2016 Sales, Profits Slip on Stronger Yen, Higher R&D Costs
February 1, 2017
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…